Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals

AIDS Patient Care and STDs

Volumn 29, Issue 7, 2015, Pages 379-383

  Cope, Rebecca ^a   Pickering, Aaron ^b   Glowa, Thomas ^c   Faulds, Samantha ^c   Veldkamp, Peter ^c   Prasad, Ramakrishna ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Baltimore Washington Medical Center   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LEDIPASVIR; RALTEGRAVIR; RILPIVIRINE; SIMEPREVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEASIBILITY STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; COINFECTION; DRUG INTERACTION; GENETICS; HEPACIVIRUS; HIV INFECTIONS; MIDDLE AGED; RETROSPECTIVE STUDY;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RIBAVIRIN; RITONAVIR;

EID: 84934288281     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2015.0004     Document Type: Article

References (41)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013;14:195-207.
3. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013;177:116-125.
4. Kirk J, Goetz MB. Human immunodeficiency virus in an aging population; A complication of success. J Am Geriatr Soc 2009;57:2129-2138.
5. Hernando V, Perez-Cachafeiro S, Lewden C, et al. Allcause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV coinfection. J Hepatol 2012;57:743-751.
6. Cacoub, P, Dabis F, Costagliola, D, et al. Burden of HIV and hepatitis C co-infection: The changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int 2015;35:65-70.
7. Pineda JA, García-García JA, Aguilar-Guisado M, et al; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46:622-630.
8. Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42:639-645.
9. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006;166:1632-1641.
10. McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007;54:S47-S56.
11. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
12. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
13. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
14. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
15. Butt AA, McGinnis K, Skanderson M, Justice AC. A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Res Hum Retroviruses 2011;27:973-979.
16. AASLD/IDSA/IAS/USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://hcvguidelines.org (Last accessed March 5, 2015).
17. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomized study. Lancet 2014; 384:1756-1765.
18. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
19. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
20. Kowdley KV, Gordon SC, Reddy KR. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
21. Olysio [package insert]. Titusville, NJ: Janssen Products, 2013.
22. Viekira Pak [package insert]. North Chicago, IL: AbbVie, 2015.
23. AASLD/IDSA/IAS/USA. Unique Patient Populations: Patients with HIV/HCV co-infection. Recommendations for testing, managing, a(Lnd treating hepatitis C. Available at: http://hcvguidelines.org (Last accessed March 5, 2015).
24. Harvoni [package insert]. Foster City, CA: Gilead, 2014.
25. Wyles DL, Sulkowski MS, Eron JJ, et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. [Abstract 1939.] Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7-11, 2014a, Boston, MA.
26. Yehia BR, Schranz AJ, Umschied CA, Lo Re V. The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLoS One 2014;9:e101554.
27. th Annual Department of Medicine Research Day, May 22, 2014, Pittsburgh, PA.
28. Cachay ER, Hill L, Wyles D, et al. The hepatitis C cascade of care among HIV infected patients: A call to address ongoing barriers to care. PLoS One. 2014;9:e102883.
29. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med 2013b;159:372.
30. Castera L, Sebastiani G, Le BB, de L, V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52:191-198.
31. HIV-Drug Interactions. The University of Liverpool. Available at: http://www.hiv-druginteractions.org (Last accessed August 29, 2014).
32. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-723.
33. nd Conference for Retroviruses and Opportunistic Infections, February 23-26, 2015, Seattle, WA.
34. EASL. Recommendations on Treatment of Hepatitis C 2014. Available at: http://easl.eu (Last accessed March 12, 2015).
35. Daklinza [package insert]. Uxbridge, UK: Bristol-Myers Squibb, 2015.
36. Karageorgopoulos D, El-Sherif O, Bhagani S, Khoo S. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014;27:36-45.
37. nd Conference for Retroviruses and Opportunistic Infections, February 23-26, 2015, Seattle, WA.
38. AASLD/IDSA/IAS/USA. Retreatment of Persons in Whom Prior Therapy Has Failed. Recommendations for testing, managing, and treating hepatitis C. Available at: http://hcvguidelines.org (Last accessed March 7, 2015).
39. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014;20:2902-2912.
40. Issur M, Gotte M. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses 2014;6:4227-4241.
41. Third annual State of HIV Primary Care National Survey. HealthHIV 2014.